Vanderbilt receives $1M grant to fund immunotherapy research in CRC

UCLA researchers receive $3M NIH grant for CRC screening follow-up in underserved communities

Researchers from the UCLA Health Jonsson Comprehensive Cancer Center were awarded a $3 million grant from NIH to improve follow-up care for colorectal cancer screening in underserved populations.

October 04, 2024

Vol.50 No.37

Clinical Roundup

Circadian disruption, gut microbiome changes linked to CRC progression in mice

Research from the University of California, Irvine revealed how disruption of the circadian clock may accelerate the progression of colorectal cancer by affecting the gut microbiome and intestinal barrier function.

October 04, 2024

Vol.50 No.37

Drugs & Targets

FDA approves Cologuard Plus Test for non-invasive CRC screening

FDA approved the Cologuard Plus test, a multitarget stool DNA test. The Cologuard Plus test is now approved for adults ages 45 and older who are at average risk for colorectal cancer.

October 04, 2024

Vol.50 No.37

Regulatory News

ODAC votes overwhelmingly in support of PD-L1 expression as predictive biomarker for efficacy of checkpoint inhibitors
Vote applies across drugs and indications

The FDA Oncologic Drugs Advisory Committee on Sept. 26 voted that PD-L1 inhibitors should not be indicated for patients with PD-L1-negative gastric/gastroesophageal junction adenocarcinoma and esophageal squamous cell carcinoma.

Alessio Pigazzi named executive medical director of colorectal surgery at City of Hope Orange County

Alessio Pigazzi was appointed executive medical director of colorectal surgery at City of Hope Orange County.

September 13, 2024

Vol.50 No.34

In Brief

ACS, Color Health to provide free at-home colorectal cancer screening kits in underserved rural communities

ACS and Color Health launched their pilot program to provide free at-home colorectal cancer screening kits to individuals in rural areas and other underserved communities, where barriers to healthcare access often hinder timely screening and early detection.

September 13, 2024

Vol.50 No.34

Vanderbilt receives $1M grant to fund immunotherapy research in CRC

YOU MAY BE INTERESTED IN

UCLA researchers receive $3M NIH grant for CRC screening follow-up in underserved communities

Circadian disruption, gut microbiome changes linked to CRC progression in mice

FDA approves Cologuard Plus Test for non-invasive CRC screening

ODAC votes overwhelmingly in support of PD-L1 expression as predictive biomarker for efficacy of checkpoint inhibitors
Vote applies across drugs and indications

Alessio Pigazzi named executive medical director of colorectal surgery at City of Hope Orange County

ACS, Color Health to provide free at-home colorectal cancer screening kits in underserved rural communities

Renew today!

Subscriber content

Can you spare 10 minutes to complete a survey?

Login

Vanderbilt receives $1M grant to fund immunotherapy research in CRC

YOU MAY BE INTERESTED IN

UCLA researchers receive $3M NIH grant for CRC screening follow-up in underserved communities

Circadian disruption, gut microbiome changes linked to CRC progression in mice

FDA approves Cologuard Plus Test for non-invasive CRC screening

ODAC votes overwhelmingly in support of PD-L1 expression as predictive biomarker for efficacy of checkpoint inhibitorsVote applies across drugs and indications

Alessio Pigazzi named executive medical director of colorectal surgery at City of Hope Orange County

ACS, Color Health to provide free at-home colorectal cancer screening kits in underserved rural communities

Can you spare 10 minutes to complete a survey?

Login

ODAC votes overwhelmingly in support of PD-L1 expression as predictive biomarker for efficacy of checkpoint inhibitors
Vote applies across drugs and indications